BRPI1007929A2 - "métodos e composições para o tratamento de neovascularização". - Google Patents

"métodos e composições para o tratamento de neovascularização".

Info

Publication number
BRPI1007929A2
BRPI1007929A2 BRPI1007929-7A BRPI1007929A BRPI1007929A2 BR PI1007929 A2 BRPI1007929 A2 BR PI1007929A2 BR PI1007929 A BRPI1007929 A BR PI1007929A BR PI1007929 A2 BRPI1007929 A2 BR PI1007929A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
treating neovascularization
neovascularization
treating
Prior art date
Application number
BRPI1007929-7A
Other languages
English (en)
Inventor
Ingeborg Stalmans
Derek Marshall
Tine Van Bergen
Victoria Smith
Original Assignee
Arresto Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arresto Biosciences Inc filed Critical Arresto Biosciences Inc
Publication of BRPI1007929A2 publication Critical patent/BRPI1007929A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI1007929-7A 2009-02-06 2010-02-05 "métodos e composições para o tratamento de neovascularização". BRPI1007929A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20720209P 2009-02-06 2009-02-06
PCT/US2010/023359 WO2010091279A1 (en) 2009-02-06 2010-02-05 Methods and compositions for treatment of neovascularization

Publications (1)

Publication Number Publication Date
BRPI1007929A2 true BRPI1007929A2 (pt) 2015-09-01

Family

ID=42540596

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007929-7A BRPI1007929A2 (pt) 2009-02-06 2010-02-05 "métodos e composições para o tratamento de neovascularização".

Country Status (13)

Country Link
US (1) US20100203062A1 (pt)
EP (1) EP2393923A4 (pt)
JP (1) JP2012517438A (pt)
KR (1) KR20110140121A (pt)
CN (1) CN102439141A (pt)
AU (1) AU2010210489A1 (pt)
BR (1) BRPI1007929A2 (pt)
CA (1) CA2751438A1 (pt)
IL (1) IL214455A0 (pt)
MX (1) MX2011008296A (pt)
RU (1) RU2011136853A (pt)
SG (1) SG173598A1 (pt)
WO (1) WO2010091279A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
CA2693310C (en) * 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
MX2012002271A (es) * 2009-08-21 2012-07-20 Gilead Biologics Inc Metodos y composiciones terapeuticas.
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
CA2771702A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
JP2013506005A (ja) * 2009-09-29 2013-02-21 ギリアド バイオロジクス，インク． 眼の繊維症の処置のための方法及び組成物
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
US20140186340A1 (en) * 2011-04-08 2014-07-03 Gilead Biologics, Inc. Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
EP3411716A1 (en) * 2016-02-03 2018-12-12 Nordic Bioscience A/S Combined biomarker measurement of fibrosis
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
GB202209624D0 (en) 2022-06-30 2022-08-17 Institute Of Cancer Res Royal Cancer Hospital Prodrugs
GB202209622D0 (en) 2022-06-30 2022-08-17 Institute Of Cancer Res Royal Cancer Hospital Compounds
JP2026523880A (ja) * 2023-06-17 2026-07-15 ナラヤナ ネトララヤ ファウンデーション 円錐角膜に対するアデノ随伴ウイルス（ａａｖ）を介したリシルオキシダーゼ遺伝子治療およびそのコンストラクト

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997854A (en) * 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US6300092B1 (en) * 1999-01-27 2001-10-09 Millennium Pharmaceuticals Inc. Methods of use of a novel lysyl oxidase-related protein
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
FR2828206B1 (fr) * 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
CA2599004C (en) * 2005-02-28 2015-05-26 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US20070021365A1 (en) * 2005-06-21 2007-01-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
IL184627A0 (en) * 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
CA2693310C (en) * 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
FR2927882B1 (fr) * 2008-02-27 2010-02-12 Aircelle Sa Structure d'entree d'air pour une nacelle d'un aeronef
US9107935B2 (en) * 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
MX2012002271A (es) * 2009-08-21 2012-07-20 Gilead Biologics Inc Metodos y composiciones terapeuticas.
CA2771702A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
JP2013506005A (ja) * 2009-09-29 2013-02-21 ギリアド バイオロジクス，インク． 眼の繊維症の処置のための方法及び組成物

Also Published As

Publication number Publication date
EP2393923A4 (en) 2012-11-14
IL214455A0 (en) 2011-09-27
KR20110140121A (ko) 2011-12-30
EP2393923A1 (en) 2011-12-14
US20100203062A1 (en) 2010-08-12
JP2012517438A (ja) 2012-08-02
WO2010091279A1 (en) 2010-08-12
CA2751438A1 (en) 2010-08-12
RU2011136853A (ru) 2013-03-20
MX2011008296A (es) 2012-03-14
CN102439141A (zh) 2012-05-02
AU2010210489A1 (en) 2011-08-25
SG173598A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0818732A2 (pt) Composições de análogo de prostaglandina e métodos para tratar condições relacionadas epiteliais.
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
PT2340042E (pt) Métodos e composições para o tratamento de cancro
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
EP2419732A4 (en) PRION-FREE NANOPARTICLE COMPOSITIONS AND METHODS
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI1009920A2 (pt) composições bacterianas para profilaxina e tratamento de doença degenerativa.
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BR112012006808A2 (pt) "composições sanitizadoras e método para sanitização de superfície"
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI1006024A2 (pt) composição cosmética emulsificada
BR112013003529A2 (pt) "composição aerada, composição de tratamento capilar método para o tratamento capilar"
BRPI1007603A2 (pt) "composição de tratamento do cabelo"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.